Directed evolution of three-finger toxin to produce serine protease inhibitors

References

• Michaud GA, Salcius M, Zhou F, et al. Analyzing antibody specificity with whole proteome microarrays. Nat Biotechnol 2003;21(12):1509–12
   Google Scholar
• Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006;6(5):343–57
   PubMed Web of Science ®Google Scholar
• Werner RG. Economic aspects of commercial manufacture of biopharmaceuticals. J Biotechnol 2004;113(1-3):171–82
   Google Scholar
• Ladner RC, Ley AC. Novel frameworks as a source of high-affinity ligands. Curr Opin Biotechnol 2001;12(4):406–10
   Google Scholar
• Skerra A. Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol 2007;18(4):295–304
   PubMed Web of Science ®Google Scholar
• Ku J, Schultz PG. Alternate protein frameworks for molecular recognition. Proc Natl Acad Sci U S A 1995;92(14):6552–6
   Google Scholar
• Ceci LR, Volpicella M, Rahbe Y, et al. Selection by phage display of a variant mustard trypsin inhibitor toxic against aphids. Plant J 2003;33(3):557–66
   Google Scholar
• Tedeschi F, Di Maro A, Facchiano A, et al. Wheat subtilisin/chymotrypsin inhibitor (WSCI) as a scaffold for novel serine protease inhibitors with a given specificity. Mol Biosyst 2012;8(12):3335–43
   Google Scholar
• Nygren PA, Skerra A. Binding proteins from alternative scaffolds. J Immunol Methods 2004;290(1–2):3–28
   PubMedGoogle Scholar
• Naimuddin M, Kobayashi S, Tsutsui C, et al. Directed evolution of a three-finger neurotoxin by using cDNA display yields antagonists as well as agonists of interleukin-6 receptor signaling. Mol Brain 2011;4:2
   Google Scholar
• Binz HK, Amstutz P, Pluckthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 2005;23(10):1257–68
   PubMed Web of Science ®Google Scholar
• Fruchart-Gaillard C, Mourier G, Blanchet G, et al. Engineering of three-finger fold toxins creates ligands with original pharmacological profiles for muscarinic and adrenergic receptors. PLoS ONE 2012;7(6):e39166
   Google Scholar
• Tsetlin V. Snake venom alpha-neurotoxins and other ‘three-finger' proteins. Eur J Biochem 1999;264(2):281–6
   PubMedGoogle Scholar
• Bourne Y, Talley TT, Hansen SB, et al. Crystal structure of a Cbtx-AChBP complex reveals essential interactions between snake alpha-neurotoxins and nicotinic receptors. EMBO J 2005;24(8):1512–22
   Google Scholar
• Teixeira-Clerc F, Menez A, Kessler P. How do short neurotoxins bind to a muscular-type nicotinic acetylcholine receptor? J Biol Chem 2002;277(28):25741–7
   Google Scholar
• Rodriguez J, Gupta N, Smith RD, Pevzner PA. Does trypsin cut before proline? J Proteome Res 2008;7(1):300–05
   Google Scholar
• Silverman GA, Bird PI, Carrell RW, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins-evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001;276(36):33293–6
   PubMed Web of Science ®Google Scholar
• Rawlings ND, Tolle DP, Barrett AJ. Evolutionary families of peptidase inhibitors. Biochem J 2004;378:705–16
   PubMed Web of Science ®Google Scholar
• Lu WT, Lakey JRT, Juang JH, et al. Effect of trypsin inhibitor on islet isolation from fresh and cold preserved rat pancreas. Transplant Proc 2003;35(1):488–9
   Google Scholar
• Kobayashi H, Gotoh J, Hirashima Y, Terao T. Inter-alpha-trypsin inhibitor bound to tumor cells is cleaved into the heavy chains and the light chain on the cell surface. J Biol Chem 1996;271(19):11362–7
   Google Scholar
• Kamiya T, Katayama Y, Kashiwagi F, Terashi A. The role of Bradykinin in mediating ischemic brain edema in rats. Stroke 1993;24(4):571–6
   Google Scholar
• Fremes SE, Wong BI, Lee E, et al. Metaanalysis of prophylactic drug-treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994;58(6):1580–8
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Yunohara N. Effects of urinary trypsin inhibitor in patients at risk for premature labor with a bulging fetal membrane. Fetal Diagn Ther 2002;17(2):69–74
   Google Scholar
• Waxler B, Rabito SF. Aprotinin: a serine protease inhibitor with therapeutic actions: its interaction with ACE inhibitors. Curr Pharm Des 2003;9(9):777–87
   PubMed Web of Science ®Google Scholar
• Naimuddin M, Kubo T. Display of disulfide-rich proteins by complementary DNA display and disulfide shuffling assisted by protein disulfide isomerase. Anal Biochem 2011;419(1):33–39
   Google Scholar
• Inagaki H, Kimoto H, Yamauchi Y, Toriba M, Kubo T. Functional characterization of Kunitz-type protease inhibitor Pr-mulgins identified from New Guinean Pseudechis australis. Toxicon 2012;59(1):74–80
   Google Scholar
• Friguet B, Chaffotte AF, Djavadiohaniance L, Goldberg ME. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent-assay. J Immunol Methods 1985;77(2):305–19
   PubMed Web of Science ®Google Scholar
• Cheng Y, Prusoff WH. Relationship between inhibition constant (Ki) and concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic-reaction. Biochem Pharmacol 1973;22(23):3099–108
   PubMed Web of Science ®Google Scholar
• Kanagawa T. Bias and artifacts in multitemplate polymerase chain reactions (PCR). J Biosci Bioeng 2003;96(4):317–23
   PubMed Web of Science ®Google Scholar
• Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 2009;13(3):245–55
   PubMed Web of Science ®Google Scholar
• Boersma YL, Pluckthun A. DARPins and other repeat protein scaffolds: advances in engineering and applications. Curr Opin Biotechnol 2011;22(6):849–57
   PubMed Web of Science ®Google Scholar
• Wurch T, Pierre A, Depil S. Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. Trends Biotechnol 2012;30(11):575–82
   PubMed Web of Science ®Google Scholar
• Gebauer M, Skerra A. Anticalins: small engineered binding proteins based on the lipocalin scaffold. Methods Enzymol 2012;503:157–88
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kouzuma Y, Miyaji T, Yonekura M. Purification, characterization, and cDNA cloning of a Bowman-Birk type trypsin inhibitor from Apios americana medikus tubers. Biosci, Biotechnol, Biochem 2008;72(1):171–8
   PubMed Web of Science ®Google Scholar
• Sweet RM, Wright HT, Janin J, et al. Crystal-structure of complex of porcine trypsin with soybean trypsin-inhibitor (Kunitz) at 2.6-A resolution. Biochemistry 1974;13(20):4212–28
   Google Scholar
• Kolte D, Bryant JW, Holsworth D, et al. Biochemical characterization of a novel high-affinity and specific plasma kallikrein inhibitor. Br J Pharmacol 2011;162(7):1639–49
   PubMed Web of Science ®Google Scholar
• Schneider L, Lumry W, Vegh A, et al. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol 2007;120(2):416–22
   PubMed Web of Science ®Google Scholar
• Christiansen SC, Zuraw BL. Update on therapeutic developments for hereditary angioedema. Allergy Asthma Proc 2009;30(5):500–05
   Google Scholar
• Shariat-Madar Z, Schmaier AH. The plasma kallikrein/kinin and renin angiotensin systems in blood pressure regulation in sepsis. J Endotoxin Res 2004;10(1):3–13
   Google Scholar
• Bode W, Chen ZG, Bartels K, et al. Refined 2 A X-ray crystal-structure of porcine pancreatic kallikrein A, a Specific trypsin-like serine proteinase: crystallization, structure determination, crystallographic refinement, structure and its comparison with bovine trypsin. J Mol Biol 1983;164(2):237–82
   Google Scholar
• Chiappinelli VA, Lee JC. Kappa-Bungarotoxin. Self-association of a neuronal nicotinic receptor probe. J Biol Chem 1985;260(10):6182–86
   Google Scholar
• Bilwes A, Rees B, Moras D, et al. X-ray structure at 1.55 A of toxin-gamma, a cardiotoxin from Naja nigricollis Venom – crystal packing reveals a model for insertion into membranes. J Mol Biol 1994;239(1):122–36
   Google Scholar